Its crucial to note that individuals with diabetes are not eligible for the Bridge program, as diabetes-related treatments should already be covered by existing health plans
For weight management, semaglutide (Wegovy) follows a different schedule: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg weekly
In this regard, it is still unknown whether tirzepatide can induce long-term cardiovascular benefits that are comparable to those of specific GLP-1 RAs or sodiumglucose cotransporter 2 inhibitors [6]
New pricing for new accounts only effective as of July 27, 2026
1 Several health conditions, including diabetes and Polycystic Ovarian Syndrome (PCOS), can affect the amount of GLP-1 released in the body or weaken the sensitivity of the receptors it binds to, leading to insulin resistance